EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation

Isaac Nuñez Hernández, Cristina Gómez Palmero, Juan Ramón Delgado, Ana Nuño, Maria Ángeles Sala González, Ana González Ageitos, Héctor Aguilar, Pablo Ayala de Miguel, Elizabeth Condori, Roberto Díaz Beveridge, Jerónimo Martínez García, Gloria Marquina und 3 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf062 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Isaac Nuñez Hernández und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Ctra. Gral. del Rosario, 145, 38010, Spain. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Mutation, Receptor, Platelet-Derived Growth Factor alpha, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asociación Española Contra el Cáncer, Blueprint Medicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma subtype. Patients with unresectable or metastatic GISTs harboring the D842V mutation in the PDGFRA gene have a poor prognosis due to intrinsic resistance to imatinib and all other approved tyrosine kinase inhibitors. Avapritinib, targeting this mutation, is the first agent approved for patients with unresectable or metastatic GIST that have the PDGFRA D842V mutation. This study assesses the effectiveness and safety of avapritinib in real-world clinical scenarios involving Spanish patients with this mutation. Materials and methods The AVARWE study is a descriptive, retrospective, multicenter observational study of 21 patients treated with avapritinib across 13 Spanish centers from June 9, 2023, to December 18, 2023. Data collected included patient demographics, disease characteristics, treatment history, and response rates based on RECIST criteria. The main outcomes, progression-free survival (PFS) and overall survival (OS), were measured, with safety assessed through adverse events documentation according to CTCAE criteria.

Results

Median PFS 35.6 was months and median OS was 42.2 months, with survival rates at 1, 5, and 3 years demonstrating avapritinib effectiveness. The objective response rate was 76.2% for partial response and 4.8% for complete response. Avapritinib enabled surgical intervention in previously unresectable cases and was generally well-tolerated, with manageable adverse events.

Conclusion

Avapritinib extends PFS and OS among patients with PDGFRA D842V-mutant GIST in real-world practice, mirroring pivotal trial outcomes. Its substantial activity supports its use as a first-line therapy for this subgroup. The manageable safety profile reinforces avapritinib viability for routine use. Given the rarity of these cases, it is advised to consult sarcoma-expert units.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsMutationReceptor, Platelet-Derived Growth Factor alphaPyrazolesPyrrolesProtein Kinase InhibitorsGastrointestinal NeoplasmsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesSpainAdultAged, 80 and overTreatment OutcomeTriazinesAvapritinib

Stichwörter der Autor:innen

PDGFRAD842V mutationGISTavapritinibgastrointestinal stromal tumoroutcomestreatment

Substanzen

Receptor, Platelet-Derived Growth Factor alphaPyrazolesPyrrolesProtein Kinase InhibitorsTriazinesAvapritinib

Autor:innen und Institutionen

  • Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Ctra. Gral. del Rosario, 145, 38010, Spain.
  • Fundación Investigación del cáncer en Canarias | FICIC, Av. Alcalde Díaz Saavedra Navarro, 31, 35001 Las Palmas de Gran Canaria, Las Palmas, Spain.
  • Hospital Universitario de Toledo, Toledo, Av. del Río Guadiana, 45007, Spain.
  • Hospital Universitario Vall d'Hebron, Pg. de la Vall d'Hebron, 119, Horta-Guinardó, 08035, Barcelona, Spain.
  • Hospital Universitario Virgen de las Nieves (HUVN), Av. de las Fuerzas Armadas, 2, Beiro, 18014 Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, Av. de Madrid, 15, Beiro, 18012 Granada, Spain.

ORCID-Profile: César Serrano

Förderung

  • Asociación Española Contra el Cáncer
  • Blueprint Medicines

Zitieren

APA

Nuñez Hernández, I., Gómez Palmero, C., Delgado, J. R., Nuño, A., Sala González, M. Á., González Ageitos, A., Aguilar, H., Ayala de Miguel, P., Condori, E., Díaz Beveridge, R., Martínez García, J., Marquina, G., Varela-Pose, V., Veas Rodríguez, J., & Serrano, C. (2025). Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation. The Oncologist. https://doi.org/10.1093/oncolo/oyaf062

Vancouver

Nuñez Hernández I, Gómez Palmero C, Delgado JR, Nuño A, Sala González MÁ, González Ageitos A, et al. Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation. The Oncologist. 2025. doi:10.1093/oncolo/oyaf062

BibTeX
@article{NuezHernndez2025,
  author = {Nuñez Hernández, Isaac and Gómez Palmero, Cristina and Delgado, Juan Ramón and Nuño, Ana and Sala González, Maria Ángeles and González Ageitos, Ana and Aguilar, Héctor and Ayala de Miguel, Pablo and Condori, Elizabeth and Díaz Beveridge, Roberto and Martínez García, Jerónimo and Marquina, Gloria and Varela-Pose, Vanesa and Veas Rodríguez, Joel and Serrano, César},
  title = {Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf062}
}
Kostenlos starten →